Amplia Therapeutics (ASX:ATX) said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.

It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.

The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.